trending Market Intelligence /marketintelligence/en/news-insights/trending/RM-xYhNgYULgk-QdVdhf5A2 content esgSubNav
In This List

Bristol-Myers' Opdivo gets US FDA approval for colorectal cancer

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Bristol-Myers' Opdivo gets US FDA approval for colorectal cancer

The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co.'s Opdivo in another cancer indication.

The therapy can now be used to fight a certain type of metastatic colorectal cancer that progressed after receiving fluoropyrimidine, oxaliplatin and irinotecan.

The indication was approved under accelerated approval supported by overall response rate and duration of response in a phase 2 trial.

Opdivo is approved for a number of cancers, including lung cancer.